The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma

$279,150R01FY2021CANIH

Fred Hutchinson Cancer Center, Seattle WA

Investigators

Evan Newellcontact

Linked publications & trials

Paper 39430319 Paper 38915597 Paper 38781964 Paper 38712065 Paper 38670099 Paper 38340724

View original record on NIH RePORTER →